Retatrutide peptide is a “three-in-one” drug that activates GLP-1, GIP and glucagon receptors. In clinical trials, retatrutide demonstrated excellent weight loss: subjects lost an average of 24.2% of their body weight in 11 months, compared to 15-20% for approved drugs in the same period.
Retatrutide peptide Dosage Trial
1 mg of subcutaneous reta
4 mg of subcutaneous reta, starting at an initial dose of 2 mg
4 mg of subcutaneous reta, starting at an initial dose of 4 mg
8 mg of subcutaneous reta, starting at an initial dose of 2 mg
8 mg of subcutaneous reta, starting at an initial dose of 4 mg
12 mg of subcutaneous reta, starting at an initial dose of 2 mg
Halfway through the study, at 24 weeks, patients in the placebo group had only reached a 1.6% weight reduction. Meanwhile, patients receiving 1 mg of retatrutide lost an average of 7.2% body weight. Across all 4 mg groups, the average weight loss was 12.9% of body mass, while 8 mg groups had an average weight loss of 17.3%. Comparatively, the group dosed with 12 mg lost an average of 17.5% of their body weight in the same time frame.
Retatrutide weight loss was even more significant by the end of the study (48 weeks), with the 12 mg group having a 24.2% weight reduction. In contrast, the placebo, 1, 4, and 8 mg groups had a 2.1%, 8.7%, 17.1%, and 22.8% body mass reduction.
Retatrutide peptide Side effects
The most common side effects of It are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were “mostly mild to moderate in severity” and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients’ heart rates on higher doses peaked but declined afterward.
in vitro In vitro, Retatrutide demonstrates similar efficacy to natural glucagon in evoking glucose production within hepatocytes. Meanwhile, in adipocytes, it surpasses native GIP in inducing lipolysis. Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity. Retatrutide demonstrates dosage‐dependent pharmacokinetics, featuring a favourable half‐life of nearly 6 days, enabling convenient weekly administration. Additionally, GLP‐1 and GCG are known to significantly delay GE in humans, while GIP may have no impact on GE. Delayed GE reduces food consumption and, therefore, leads to weight reduction.
More Introduction:https://en.wikipedia.org/wiki/Retatrutide
